Cisplatin-induced hearing loss in a child with deafness susceptibility gene
10.3760/cma.j.cn114015-20191230-01082
- VernacularTitle:顺铂致耳聋易感基因携带患儿听力下降
- Author:
Rui WANG
1
;
Yanqing SONG
1
;
Lichao MAO
1
;
Xiangfeng WANG
1
Author Information
1. 吉林大学第一医院药学部，长春 130021
- Publication Type:Journal Article
- Keywords:
Cisplatin;
Ototoxicity;
Pharmacogenomic testing
- From:
Adverse Drug Reactions Journal
2021;23(1):43-44
- CountryChina
- Language:Chinese
-
Abstract:
A 17-month-old female infant received combination chemotherapy with cisplatin, etoposide, and bleomycin (IV infusion of cisplatin 8.5 mg on day 1 to 5, IV infusion of etoposide 42 mg on day 1 to 5, IV infusion of bleomycin 6 units on day 1) after yolk sac tumor resection. Two weeks after finishing the chemotherapy, the child developed hearing loss. Her hearing thresholds evaluation showed 32 decibel for the left ear and 45 decibel for the right ear. Two women in her mother′s family were known to be with acquired deafness by questioning the family history. The results of deafness gene screening showed that the child was a carrier of the mitochondrion 12SrRNA gene m.1555A>G site homogeneous mutation, so it was considered that the hearing loss of the child was related to her deafness susceptibility gene and ototoxicity of cisplatin.
